$TVTX
Travere Therapeutics Inc Stock $tvtx

$tvtx Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000143853319000024 Filed on August 06, 2019

Income Statement

Concept	2019 Q3	2019 Q2	2018 Q2
Revenue	$44.37M	$44.71M	$41.34M
YoY Change	9.01%	8.15%	6.54%
Cost Of Revenue	$1.513M	$979.0K	$1.178M
YoY Change	33.54%	-16.89%	47.8%
Gross Profit	$42.86M	$43.73M	$40.16M
YoY Change	8.31%	8.89%	5.67%
Gross Profit Margin	96.59%	97.81%	97.15%
Selling, General & Admin	$29.78M	$38.97M	$25.10M
YoY Change	14.07%	55.26%	-12.95%
% of Gross Profit	69.48%	89.12%	62.5%
Research & Development	$33.22M	$37.93M	$34.46M
YoY Change	2.38%	10.08%	76.88%
% of Gross Profit	77.51%	86.75%	85.81%
Depreciation & Amortization	$5.380M	$4.840M	$4.640M
YoY Change	12.08%	4.31%	4.5%
% of Gross Profit	12.55%	11.07%	11.55%
Operating Expenses	$78.81M	$81.24M	$62.90M
YoY Change	3.3%	29.16%	20.04%
Operating Profit	-$34.44M	-$36.53M	-$21.56M
YoY Change	-3.22%	69.43%	58.55%
Interest Expense	-$4.547M	-$4.817M	-$1.057M
YoY Change	79.51%	355.72%	60.64%
% of Operating Profit
Other Income/Expense, Net	-$2.576M	-$2.103M	-$602.0K
YoY Change	-86.09%	249.34%	-61.31%
Pretax Income	-$37.01M	-$38.63M	-$22.16M
YoY Change	-31.59%	74.32%	46.25%
Income Tax	-$523.0K	$69.00K	$167.0K
% Of Pretax Income
Net Earnings	-$36.49M	-$38.70M	-$22.33M
YoY Change	-33.07%	73.32%	68.79%
Net Earnings / Revenue	-82.23%	-86.57%	-54.02%
Basic Earnings Per Share			-$0.56
Diluted Earnings Per Share	-$849.8K	-$922.3K	-$0.56
COMMON SHARES
Basic Shares Outstanding	42.95M shares	41.44M shares	39.94M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q3	2019 Q2	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$296.1M	$298.4M	$255.7M
YoY Change	-15.61%	16.7%	-13.61%
Cash & Equivalents	$65.19M	$75.66M	$89.31M
Short-Term Investments	$230.9M	$222.7M	$166.4M
Other Short-Term Assets	$10.60M	$10.60M	$5.500M
YoY Change	89.29%	92.73%	-8.33%
Inventory	$5.264M	$5.050M	$5.388M
Prepaid Expenses
Receivables	$16.80M	$15.50M	$12.32M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$439.7M	$457.0M	$278.9M
YoY Change	-12.58%	63.85%	-12.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.910M	$3.015M	$3.455M
YoY Change	-12.43%	-12.74%	36.02%
Goodwill	$936.0K	$936.0K	$936.0K
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$0.00	$15.00M	$15.00M
YoY Change	-100.0%	0.0%
Other Assets	$12.45M	$12.70M	$5.351M
YoY Change	68.44%	137.38%	47.49%
Total Long-Term Assets	$174.1M	$190.6M	$212.2M
YoY Change	-18.34%	-10.21%	13.2%
TOTAL ASSETS
Total Short-Term Assets	$439.7M	$457.0M	$278.9M
Total Long-Term Assets	$174.1M	$190.6M	$212.2M
Total Assets	$613.8M	$647.6M	$491.1M
YoY Change	-14.29%	31.85%	-3.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.83M	$12.52M	$7.847M
YoY Change	48.51%	59.54%	-13.54%
Accrued Expenses	$47.87M	$50.56M	$35.27M
YoY Change	10.44%	43.34%	27.8%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$45.40M
YoY Change	-100.0%	-100.0%
Total Short-Term Liabilities	$88.02M	$90.59M	$103.5M
YoY Change	-11.87%	-12.47%	29.98%
LONG-TERM LIABILITIES
Long-Term Debt	$202.4M	$199.9M	$0.00
YoY Change	4.98%		-100.0%
Other Long-Term Liabilities	$21.49M	$22.10M	$4.880M
YoY Change	339.86%	352.91%	26.72%
Total Long-Term Liabilities	$21.49M	$22.10M	$4.880M
YoY Change	339.86%	352.91%	26.72%
TOTAL LIABILITIES
Total Short-Term Liabilities	$88.02M	$90.59M	$103.5M
Total Long-Term Liabilities	$21.49M	$22.10M	$4.880M
Total Liabilities	$367.9M	$370.5M	$203.2M
YoY Change	-7.37%	82.37%	-3.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$386.2M	-$349.7M	-$208.0M
YoY Change	47.08%	68.09%	46.26%
Common Stock	$631.0M	$626.0M	$497.2M
YoY Change	8.28%	25.91%	13.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$246.0M	$277.1M	$288.0M
YoY Change
Total Liabilities & Shareholders Equity	$613.8M	$647.6M	$491.1M
YoY Change	-14.29%	31.85%	-3.15%

Cashflow Statement

Concept	2019 Q3	2019 Q2	2018 Q2
OPERATING ACTIVITIES
Net Income	-$36.49M	-$38.70M	-$22.33M
YoY Change	-33.07%	73.32%	68.79%
Depreciation, Depletion And Amortization	$5.380M	$4.840M	$4.640M
YoY Change	12.08%	4.31%	4.5%
Cash From Operating Activities	-$14.12M	-$19.11M	-$2.760M
YoY Change	262.05%	592.39%	-150.46%
INVESTING ACTIVITIES
Capital Expenditures	-$4.220M	-$3.390M	-$3.730M
YoY Change	9.61%	-9.12%	23.92%
Acquisitions
YoY Change
Other Investing Activities	$8.680M	$28.62M	$31.65M
YoY Change	-105.5%	-9.57%	-32.36%
Cash From Investing Activities	$4.460M	$25.23M	$27.91M
YoY Change	-102.76%	-9.6%	-36.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-740.0K	-320.0K	3.080M
YoY Change	-100.32%	-110.39%	-262.11%
NET CHANGE
Cash From Operating Activities	-14.12M	-19.11M	-2.760M
Cash From Investing Activities	4.460M	25.23M	27.91M
Cash From Financing Activities	-740.0K	-320.0K	3.080M
Net Change In Cash	-10.40M	5.800M	28.23M
YoY Change	-115.88%	-79.45%	-40.35%
FREE CASH FLOW
Cash From Operating Activities	-$14.12M	-$19.11M	-$2.760M
Capital Expenditures	-$4.220M	-$3.390M	-$3.730M
Free Cash Flow	-$9.900M	-$15.72M	$970.0K
YoY Change	19700.0%	-1720.62%	-88.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2019Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	dei	Entity Central Index Key EntityCentralIndexKey	0001438533
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41389524	shares
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42899318	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41389524	shares
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42899318	shares
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2019-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36257
	dei	Entity Registrant Name EntityRegistrantName	RETROPHIN, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-4842691
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3721 Valley Centre Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
	dei	City Area Code CityAreaCode	888
	dei	Local Phone Number LocalPhoneNumber	969-7879
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	RTRX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42954151	shares
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75657000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	102873000	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	350243000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	368668000	USD
CY2019Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15451000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12662000	USD
CY2019Q2	us-gaap	Inventory Net InventoryNet	5050000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	5619000	USD
CY2019Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9164000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4140000	USD
CY2019Q2	us-gaap	Prepaid Taxes PrepaidTaxes	1450000	USD
CY2018Q4	us-gaap	Prepaid Taxes PrepaidTaxes	1716000	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	457015000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	495678000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3015000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3146000	USD
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12702000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7709000	USD
CY2019Q2	us-gaap	Equity Method Investments EquityMethodInvestments	15000000	USD
CY2018Q4	us-gaap	Equity Method Investments EquityMethodInvestments	15000000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	158906000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	186691000	USD
CY2019Q2	us-gaap	Goodwill Goodwill	936000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	936000	USD
CY2019Q2	us-gaap	Assets Assets	647574000	USD
CY2018Q4	us-gaap	Assets Assets	709160000	USD
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	12519000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6954000	USD
CY2019Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	50557000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	49695000	USD
CY2019Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	8417000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6165000	USD
CY2019Q2	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	19094000	USD
CY2018Q4	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	19350000	USD
CY2019Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	USD
CY2018Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	22457000	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	90587000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	104621000	USD
CY2019Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	199891000	USD
CY2018Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	195091000	USD
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	22102000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	17545000	USD
CY2019Q2	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	57905000	USD
CY2018Q4	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	73650000	USD
CY2019Q2	us-gaap	Liabilities Liabilities	370485000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	390907000	USD
CY2019Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2019Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	625999000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	589795000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-349695000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-270017000	USD
CY2019Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	781000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1529000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	277089000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	318253000	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	647574000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	709160000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44707000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41337000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	84277000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	79769000	USD
CY2019Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	979000	USD
CY2018Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1178000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1996000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2791000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37934000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34460000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	71377000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	59096000	USD
CY2019Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	38970000	USD
CY2018Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	25100000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	71639000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	51568000	USD
CY2019Q2	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	3353000	USD
CY2018Q2	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	2159000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	6522000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	5786000	USD
CY2019Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2018Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	25500000	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2019Q2	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	0	USD
CY2018Q2	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	0	USD
	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	18000000	USD
	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	0	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	81236000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	62897000	USD
	us-gaap	Operating Expenses OperatingExpenses	159034000	USD
	us-gaap	Operating Expenses OperatingExpenses	119241000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-36529000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-21560000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-74757000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-39472000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	125000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-403000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-177000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-282000	USD
CY2019Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2589000	USD
CY2018Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	858000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	5408000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1655000	USD
CY2019Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4817000	USD
CY2018Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1057000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-9682000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2212000	USD
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2103000	USD
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-602000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4451000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-839000	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-38632000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22162000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-79208000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-40311000	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	69000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	167000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	470000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	396000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-38701000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-22329000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-79678000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-40707000	USD
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.92
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.91
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.03
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41957860	shares
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40061045	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41685599	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39641334	shares
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-38701000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-22329000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-79678000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-40707000	USD
CY2019Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-91000	USD
CY2018Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	2000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	27000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	24000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	815000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	375000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	2284000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-161000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37977000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21952000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-77367000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40844000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-79678000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-40707000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9742000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8991000	USD
	rtrx	Noncash Interest Expense NoncashInterestExpense	798000	USD
	rtrx	Noncash Interest Expense NoncashInterestExpense	767000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	580000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-647000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4933000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	325000	USD
	rtrx	Provision For Inventory ProvisionForInventory	-358000	USD
	rtrx	Provision For Inventory ProvisionForInventory	378000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	11947000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	10160000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	345000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	0	USD
	rtrx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	-11478000	USD
	rtrx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	5786000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-2767000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-5563000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	25500000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-14000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-214000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-60000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-199000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2396000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1431000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-918000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	433000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	10101000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-637000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6305000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2811000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	7195000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2485000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39601000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17494000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	21000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	601000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	7347000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	11389000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	115998000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	63565000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	94812000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	29519000	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	15000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	13818000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7056000	USD
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1722000	USD
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	7947000	USD
	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1034000	USD
	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1000000	USD
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	0	USD
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	500000	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2140000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	317000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6890000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	1005000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	800000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1434000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	383000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-34000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-27216000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10089000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102873000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	99394000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75657000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	89305000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	285712000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	299475000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5577000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5372000	USD
CY2019Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	12000	USD
CY2018Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	2633000	USD
CY2018Q2	rtrx	Exercise Of Warrants And Reclassification Of Derivative Liability ExerciseOfWarrantsAndReclassificationOfDerivativeLiability	1533000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	815000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	375000	USD
CY2019Q2	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-91000	USD
CY2018Q2	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	2000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	22590000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1176000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	928000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-38701000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-22329000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	277089000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	287989000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	318253000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	293134000	USD
CY2018Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	15710000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11947000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	9915000	USD
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	317000	USD
	rtrx	Exercise Of Warrants And Reclassification Of Derivative Liability ExerciseOfWarrantsAndReclassificationOfDerivativeLiability	2140000	USD
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	6890000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	2284000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-161000	USD
	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	26000	USD
	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	24000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	22590000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1350000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1044000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-79678000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-40707000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	277089000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	287989000	USD
	us-gaap	Nature Of Operations NatureOfOperations	DESCRIPTION OF BUSINESS<div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;color:#006ebf;font-style:normal;font-weight:bold;text-decoration:none;">Organization and Description of Business</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Retrophin, Inc. (“we”, “our”, “us”, “Retrophin” and the “Company”) refers to Retrophin, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Retrophin is a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing and delivering life-changing therapies to people living with rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with rare diseases and that we believe offer attractive growth characteristics.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><span style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;">The Company is developing the following pipeline products:</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is developing fosmetpantotenate (RE-024), a novel small molecule, as a potential treatment for </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">pantothenate kinase-associated neurodegeneration (“PKAN”)</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. PKAN is a genetic neurodegenerative disorder that is typically diagnosed in the first decade of life.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Sparsentan</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">,</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> also known as RE-021, is an investigational product candidate with a dual mechanism of action, a potent angiotensin receptor blocker (“ARB”) and selective endothelin receptor antagonist (“ERA”), with in vitro selectivity toward endothelin receptor type A. Sparsentan is currently being evaluated in two pivotal Phase 3 clinical studies in the following indications:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#4c4c4c;font-weight:bold;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Focal segmental glomerulosclerosis ("FSGS") is a rare kidney disease characterized by proteinuria where the glomeruli become progressively scarred. FSGS is a leading cause of end-stage renal disease.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#4c4c4c;font-weight:bold;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Immunoglobulin A nephropathy ("IgAN") is an immune-complex-mediated glomerulonephritis characterized by hematuria, proteinuria, and variable rates of progressive renal failure. IgAN is the most common primary glomerular disease.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In September 2017, the Company entered into a three-way Cooperative Research and Development Agreement ("CRADA") with the National Institutes of Health’s National Center for Advancing Translational Sciences ("NCATS") and patient advocacy foundation NGLY1.org to collaborate on research efforts aimed at the identification of potential small molecule therapeutics for NGLY1 deficiency.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In June 2019, the Company announced that it has entered into a three-way CRADA with NCATS and patient advocacy foundation Alagille Syndrome Alliance ("ALGSA") to collaborate on research efforts aimed at the identification and development of potentially novel therapeutics for Alagille syndrome ("ALGS"). </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><span style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;">The Company sells the following </span><span style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;"><span>three</span></span><span style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;"> products:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Chenodal (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has been the standard of care for cerebrotendinous xanthomatosis ("CTX") patients for more than three decades and the Company is currently pursuing adding this indication to the label.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Cholbam (cholic acid capsules) is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</span></div></td></tr></table><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</span></div><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Thiola (tiopronin tablets) is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. On June 28, 2019, the Company </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">announced that the U.S. Food and Drug Administration ("FDA") approved 100 mg and 300 mg tablets of THIOLA® EC (tiopronin), a new enteric-coated formulation of THIOLA® (tiopronin), to be used for the treatment of cystinuria.</span></div>
CY2019Q2	rtrx	Number Of Products Sold NumberOfProductsSold	3	product
CY2019Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	350200000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44707000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41337000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	84277000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	79769000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	116000000.0	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	94800000	USD
CY2019Q2	us-gaap	Marketable Securities MarketableSecurities	350243000	USD
CY2018Q4	us-gaap	Marketable Securities MarketableSecurities	368668000	USD
CY2019Q2	rtrx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	222408000	USD
CY2019Q2	rtrx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	358000	USD
CY2019Q2	rtrx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	49000	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	222717000	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	127526000	USD
CY2019Q2	rtrx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	126833000	USD
CY2019Q2	rtrx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	700000	USD
CY2019Q2	rtrx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	7000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	14000000.0	USD
CY2019Q1	rtrx	Operating Lease Incentive Tenant Improvements OperatingLeaseIncentiveTenantImprovements	1800000	USD
CY2019Q2	rtrx	Development Funding Creditable Against Purchase Option DevelopmentFundingCreditableAgainstPurchaseOption	2831000	USD
CY2019Q2	rtrx	Development Funding DevelopmentFunding	19922000	USD
CY2019Q2	rtrx	Development Funding Paid DevelopmentFundingPaid	19308000	USD
CY2019Q2	rtrx	Remaining Development Funding Payable RemainingDevelopmentFundingPayable	614000	USD
CY2016Q3	rtrx	Lessee Operating Lease Square Footage Leased LesseeOperatingLeaseSquareFootageLeased	45000	sqft
CY2016Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P7Y7M
CY2016Q3	rtrx	Operating Lease Incentive Tenant Improvements OperatingLeaseIncentiveTenantImprovements	2300000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.077
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y7M
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7900000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	11300000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1318000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2613000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2486000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2560000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2637000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1585000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	13199000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2278000	USD
CY2019Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	10921000	USD
CY2019Q2	rtrx	Operating Lease Incentive Tenant Improvements OperatingLeaseIncentiveTenantImprovements	1703000	USD
CY2019Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	349241000	USD
CY2019Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1058000	USD
CY2019Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	56000	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	350243000	USD
CY2018Q4	rtrx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	209137000	USD
CY2018Q4	rtrx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	0	USD
CY2018Q4	rtrx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	662000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	208475000	USD
CY2018Q4	rtrx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	160810000	USD
CY2018Q4	rtrx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	22000	USD
CY2018Q4	rtrx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	639000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	160193000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	369947000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	22000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1301000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	368668000	USD
CY2019Q2	us-gaap	Cost Method Investments CostMethodInvestments	15000000.0	USD
CY2018Q1	rtrx	Business Combination Option Agreement Purchase Price BusinessCombinationOptionAgreementPurchasePrice	65000000.0	USD
CY2018Q1	rtrx	Business Combination Option Agreement Purchase Price Percent Transferred In Cash BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash	0.20
CY2018Q1	rtrx	Business Combination Option Agreement Purchase Price Percent Transferred By Issuance Of Equity BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity	0.80
CY2018Q4	rtrx	Business Combination Option Agreement Share Price BusinessCombinationOptionAgreementSharePrice	21.40
CY2018Q1	rtrx	Business Combination Option Agreement Percent Of Consideration Paid In Cash If Share Price Falls Below Share Price Threshold BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold	1
CY2018Q1	rtrx	Business Combination Option Agreement Contingent Consideration BusinessCombinationOptionAgreementContingentConsideration	25000000.0	USD
CY2019Q2	rtrx	Noncreditable Development Funding Commitment NoncreditableDevelopmentFundingCommitment	17091000	USD
CY2019Q2	rtrx	Straight Line Lease Expense In Excess Of Cash Payments StraightLineLeaseExpenseInExcessOfCashPayments	1622000	USD
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7596000	USD
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7596000	USD
CY2019Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2674000	USD
CY2019Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8247000	USD
CY2019Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	10921000	USD
CY2019Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1300000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75657000	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	350243000	USD
CY2019Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	425900000	USD
CY2019Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	76999000	USD
CY2019Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	76999000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102873000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	368668000	USD
CY2018Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	471541000	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	93000000	USD
CY2018Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	93000000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	6522000	USD
CY2019Q2	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	3400000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	6500000	USD
	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	18000000.0	USD
CY2018Q2	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	2200000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	5800000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	158900000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	237427000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	255643000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	78521000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	68952000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	158906000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	186691000	USD
CY2019Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4856000	USD
CY2018Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4495000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9587000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8694000	USD
CY2019Q2	us-gaap	Debt Instrument Repurchase Amount DebtInstrumentRepurchaseAmount	23400000	USD
CY2019Q2	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	1300000	shares
CY2019Q2	rtrx	Government Rebates Payable GovernmentRebatesPayable	6024000	USD
CY2018Q4	rtrx	Government Rebates Payable GovernmentRebatesPayable	8464000	USD
CY2019Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	10122000	USD
CY2018Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	10446000	USD
CY2019Q2	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	6912000	USD
CY2018Q4	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	6805000	USD
CY2019Q2	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	21011000	USD
CY2018Q4	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	16515000	USD
CY2019Q2	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	3422000	USD
CY2018Q4	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	2990000	USD
CY2019Q2	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	3066000	USD
CY2018Q4	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	4475000	USD
CY2019Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	50557000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	49695000	USD
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41957860	shares
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-38701000	USD
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.92
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40061045	shares
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-22329000	USD
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41685599	shares
	us-gaap	Net Income Loss NetIncomeLoss	-79678000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.91
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39641334	shares
	us-gaap	Net Income Loss NetIncomeLoss	-40707000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.03
CY2019Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16500000	shares
CY2018Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10600000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16600000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10500000	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4800000	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	18.62
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5748000	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5426000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12268000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10035000	USD
CY2018Q2	rtrx	Classof Warrantor Right Common Stock Issued Upon Exerciseof Warrants ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants	255445	shares
	rtrx	Classof Warrantor Right Common Stock Issued Upon Exerciseof Warrants ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants	424057	shares
CY2018Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1500000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2100000	USD
CY2019Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2018Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.008
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.006
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.010
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	200000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	500000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	400000	USD
CY2019Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4220000	USD
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4689000	USD
CY2019Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	830000	USD
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	930000	USD
CY2019Q2	us-gaap	Inventory Net InventoryNet	5050000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	5619000	USD
CY2019Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2000000.0	USD
CY2018Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1800000	USD
CY2019Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15500000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12700000	USD
CY2016	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-2300000	USD
CY2017	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-5700000	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1000000.0	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	25500000	USD
	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	18000000.0	USD
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-7500000	USD
CY2016Q2	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	500000	USD
CY2016Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	25000000.0	USD

Files In Submission

Name	View Source	Status
0001438533-19-000024-index-headers.html	Edgar Link	pending
0001438533-19-000024-index.html	Edgar Link	pending
0001438533-19-000024.txt	Edgar Link	pending
0001438533-19-000024-xbrl.zip	Edgar Link	pending
ex06302019102.htm	Edgar Link	pending
ex06302019311.htm	Edgar Link	pending
ex06302019312.htm	Edgar Link	pending
ex06302019321.htm	Edgar Link	pending
ex06302019322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
leasefootprinta03.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pipelinechartq22019a03.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
rtrx-20190630x10q.htm	Edgar Link	pending
rtrx-20190630x10q_htm.xml	Edgar Link	completed
rtrx-20190805.xsd	Edgar Link	pending
rtrx-20190805_cal.xml	Edgar Link	unprocessable
rtrx-20190805_def.xml	Edgar Link	unprocessable
rtrx-20190805_lab.xml	Edgar Link	unprocessable
rtrx-20190805_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TVTX
Travere Therapeutics Inc Stock $tvtx

2019 Q3 Form 10-Q Financial Statement

#000143853319000024 Filed on August 06, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX Travere Therapeutics Inc Stock $tvtx

2019 Q3 Form 10-Q Financial Statement

#000143853319000024 Filed on August 06, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX
Travere Therapeutics Inc Stock $tvtx